NBIX
Neurocrine Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
FDA Approved
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NBIX
Neurocrine Biosciences, Inc.
A leading neuroscience-focused biopharmaceutical company that develops pharmaceuticals for neurological, endocrine and psychiatric disorders
12780 El Camino Real, San Diego, California 92130
--
Neurocrine Biosciences, Inc., was incorporated in California in January 1992 and re-incorporated in Delaware in May 1996. The company, a biopharmaceutical company focused on neuroscience, has a simple purpose: to relieve pain for people with huge needs, but few options. For three decades, the company has used unique insights into neuroscience and the interconnections between brain and body systems to advance medicines for the treatment of underaddressed neurological, neuroendocrine and neuropsychiatric diseases, and they will continue to relentlessly pursue medicines to alleviate the burden of debilitating diseases and disorders.
Earnings Call
Q2/2025
Estimate EPS1.47
Actual EPS1.65
Estimate Revenue653.87M
Actual Revenue687.50M
Contradictions in Focus: Analyzing INGREZZA and Crinecerfont's Market Dynamics and Pricing Strategies
Aug 03,2025 05:42
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS2.07
Actual EPS2.17
Estimate Revenue747.22M
Actual Revenue794.90M
Neurocrine Biosciences' Q3 2025: Contradictions Emerge on Crenessity Launch, Ingrezza Pricing, Market Share, and Sales Force Impact
Oct 28,2025 10:45
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
NBIX has released its 2025 Q3 earnings. EPS was reported at 2.17, versus the expected 2.07, beating expectations. The chart below visualizes how NBIX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NBIX has released its 2025 Q3 earnings report, with revenue of 794.90M, reflecting a YoY change of 27.78%, and net profit of 209.50M, showing a YoY change of 61.40%. The Sankey diagram below clearly presents NBIX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
